NRX Pharmaceuticals (NRXP) Stock Forecast & Price Target

NRX Pharmaceuticals is attractive fundamentally because its lead franchise centers on NRX-100 and NRX-101, known or closely related molecules with substantial existing efficacy and safety data, reducing scientific risk versus earlier-stage biotech peers. The FDA has already engaged on a broad evidence package, including 65,000+ patients for NRX-100, while KETAFREE has completed first-round review with no major drug-component deficiencies and a current GDUFA date of November 10, 2026, supporting near-term regulatory optionality. In addition, the balance sheet was strengthened by a $22.3 million underwritten offering to $26.7 million of cash at June 30, the DARPA-backed SPARC-TMS program brings more than $11.5 million of anticipated non-dilutive funding, and manufacturing readiness for 5 million launch units adds credible commercial leverage.

NRX Pharmaceuticals is a high-risk clinical-stage company whose core programs still face major clinical and regulatory uncertainty, especially given the limited precedent for treating bipolar depression with suicidal ideation. Despite a large addressable market, Q2 2026 revenue was only $1.1 million versus estimates of $3.0–16.6 million, while the net loss widened to $16.5 million, underscoring weak near-term operating leverage and no company guidance. The outlook is further pressured by expected annual gross equity raises of about $25 million in 2026E-2028E, which could dilute shareholders as the company funds late-stage development, commercial build-out, and HOPE integration.